来源: MarketWatch ↗
Novartis’s failed trial for cholesterol drug leads to broad biopharma selloff
|
暂时无法翻译，请重试。
来源报道重点
Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.
在 MarketWatch 阅读原始报道 ↗